Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Emblem Corp EMMBF

"Emblem Corp is a licensed producer of medical cannabis. It is intended to cultivate and cure cannabis for medicinal use. The group operates in the business segment of production and sale of medical cannabis."


OTCPK:EMMBF - Post by User

Post by deminimison Jan 24, 2018 10:02am
331 Views
Post# 27422906

New Investor Presentation

New Investor PresentationWhat’s this? Emblem is actually trying to engage with current and potential new investors??

https://emblemcorp.com/wp-content/uploads/2018/01/EM-IR-Deck-01-18.pdf

interesting tidbits:

None of the 3 founders are listed in the current managment team but John Stewart is still there. They are branding this as Emblem 2.0. Given everything that has happened in the last year I think this is a great thing.

They are hiring a Chief Marketing Officer.

The greenhouse is now projected to be completed by Jan 2019 and is referred to as “phase 1”. Building a smaller greenhouse is smart, building 1 Million sq ft in one go is very time consuming and will take a VERY long time to scale up to 100% capacity. Hopefully we see several more phases announced in the very near future. Maybe something like a new phase every 6 months similar to Aphria’s expansion plans.

The oral spray being developed with Dosecann is expected to be done and available for sales in Q3.

Current patient count is 2,800. Honestly, I’m not impressed with that. Patient aquisition needs to seriously ramp up.
<< Previous
Bullboard Posts
Next >>